Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMTX NASDAQ:NAMS NASDAQ:VKTX NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMTXImmatics$5.84-1.4%$5.97$3.30▼$13.09$709.24M1.02775,587 shs403,841 shsNAMSNewAmsterdam Pharma$24.51-7.8%$23.58$14.06▼$27.35$2.77B-0.01893,019 shs916,899 shsVKTXViking Therapeutics$25.07-2.6%$31.08$18.92▼$81.73$2.82B0.734.78 million shs2.32 million shsXENEXenon Pharmaceuticals$36.36-2.3%$34.89$26.74▼$46.00$2.81B1.17872,175 shs353,119 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMTXImmatics+1.89%+3.50%-7.79%-3.27%-49.36%NAMSNewAmsterdam Pharma-1.12%+3.66%+6.40%+31.62%+64.60%VKTXViking Therapeutics-0.50%-2.98%-35.42%-1.30%-57.69%XENEXenon Pharmaceuticals+0.30%-3.67%+3.42%+13.61%-3.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMTXImmatics$5.84-1.4%$5.97$3.30▼$13.09$709.24M1.02775,587 shs403,841 shsNAMSNewAmsterdam Pharma$24.51-7.8%$23.58$14.06▼$27.35$2.77B-0.01893,019 shs916,899 shsVKTXViking Therapeutics$25.07-2.6%$31.08$18.92▼$81.73$2.82B0.734.78 million shs2.32 million shsXENEXenon Pharmaceuticals$36.36-2.3%$34.89$26.74▼$46.00$2.81B1.17872,175 shs353,119 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMTXImmatics+1.89%+3.50%-7.79%-3.27%-49.36%NAMSNewAmsterdam Pharma-1.12%+3.66%+6.40%+31.62%+64.60%VKTXViking Therapeutics-0.50%-2.98%-35.42%-1.30%-57.69%XENEXenon Pharmaceuticals+0.30%-3.67%+3.42%+13.61%-3.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMTXImmatics 2.83Moderate Buy$14.67151.36% UpsideNAMSNewAmsterdam Pharma 2.90Moderate Buy$41.5569.48% UpsideVKTXViking Therapeutics 3.00Buy$87.50249.09% UpsideXENEXenon Pharmaceuticals 3.00Buy$53.3046.59% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, NAMS, VKTX, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.009/2/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.008/25/2025NAMSNewAmsterdam PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.008/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.008/15/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/12/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/12/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $55.008/12/2025XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $43.008/7/2025NAMSNewAmsterdam PharmaRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $39.007/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $38.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMTXImmatics$168.65M4.21$0.25 per share23.78$5.12 per share1.14NAMSNewAmsterdam Pharma$45.56M60.60N/AN/A$8.20 per share2.99VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/AXENEXenon Pharmaceuticals$9.43M297.32N/AN/A$9.90 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest IMTX, NAMS, VKTX, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMTXImmaticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMTXImmaticsN/A8.808.80NAMSNewAmsterdam PharmaN/A21.0821.08VKTXViking TherapeuticsN/A25.8625.86XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMTXImmatics64.41%NAMSNewAmsterdam Pharma89.89%VKTXViking Therapeutics76.03%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipIMTXImmatics3.30%NAMSNewAmsterdam Pharma20.84%VKTXViking Therapeutics4.10%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMTXImmatics260121.55 million117.54 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableIMTX, NAMS, VKTX, and XENE HeadlinesRecent News About These CompaniesWhy Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?September 10 at 12:30 PM | zacks.comAlliancebernstein L.P. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 9 at 4:57 AM | marketbeat.comParkman Healthcare Partners LLC Decreases Stake in Xenon Pharmaceuticals Inc. $XENESeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Purchases 78,390 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 7, 2025 | marketbeat.comWells Fargo & Company Reiterates Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Trims Position in Xenon Pharmaceuticals Inc. $XENESeptember 5, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comInvestors Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)September 5, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Now Covered by Wells Fargo & CompanySeptember 5, 2025 | americanbankingnews.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at Royal Bank Of CanadaSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Has $4.28 Million Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comFirst Light Asset Management LLC Sells 532,676 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE is Vestal Point Capital LP's 9th Largest PositionSeptember 4, 2025 | marketbeat.comBirchview Capital LP Has $705,000 Stake in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 646,271 Shares of Xenon Pharmaceuticals Inc. $XENESeptember 4, 2025 | marketbeat.comRoyal Bank Of Canada Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE)September 4, 2025 | americanbankingnews.comXenon Pharmaceuticals assumed with an Overweight at Wells FargoSeptember 3, 2025 | msn.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comAnalysts Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Price Target at $53.20September 1, 2025 | americanbankingnews.comDriehaus Capital Management LLC Raises Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, NAMS, VKTX, and XENE Company DescriptionsImmatics NASDAQ:IMTX$5.84 -0.09 (-1.44%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.NewAmsterdam Pharma NASDAQ:NAMS$24.51 -2.09 (-7.85%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Viking Therapeutics NASDAQ:VKTX$25.06 -0.68 (-2.62%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Xenon Pharmaceuticals NASDAQ:XENE$36.36 -0.86 (-2.31%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
